CytomX Therapeutics, Inc.
CytomX Therapeutics, Inc. (Nasdaq: CTMX) is a clinical-stage, oncology-focused biopharmaceutical company developing conditionally activated biologic therapies using its PROBODY platform. The platform uses peptide masks and protease-cleavable linkers designed to keep therapies inactive in healthy tissues and activate… From the company’s description.
Over the twelve months to Sep 30, 2026, CytomX Therapeutics, Inc. reported revenue of $14.03M, down 87.7% from a year earlier, and a net loss of $85.42M. Its operating margin was −676.4%, and operations used $50.21M in cash. In fiscal 2025, it reported revenue of $76.20M, down 44.8% from fiscal 2024, and a net loss of $17.37M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What CytomX Therapeutics, Inc. does
In the company’s own words
CytomX Therapeutics, Inc. (Nasdaq: CTMX) is a clinical-stage, oncology-focused biopharmaceutical company developing conditionally activated biologic therapies using its PROBODY platform. The platform uses peptide masks and protease-cleavable linkers designed to keep therapies inactive in healthy tissues and activate them in the tumor microenvironment. CytomX’s lead candidate, Varsetatug masetecan, is a masked antibody-drug conjugate targeting EpCAM, initially under study for late-line metastatic colorectal cancer; its pipeline also includes CX-801, a masked interferon alfa-2b cytokine being evaluated in advanced melanoma as monotherapy and with pembrolizumab. The platform supports additional modalities, including T-cell engagers, cytokines and mRNA, through internal programs and collaborations with biopharmaceutical partners. The company’s business centers on research and development rather than marketed products, and it seeks to advance candidates itself or with partners. In March 2026, CytomX reported that 93 patients had been enrolled in the Varsetatug masetecan Phase 1 study. Its website is www.cytomx.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1501989
- SIC
- 2834
Financial performance, year by year
Fiscal 2015–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns CytomX Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · CytomX Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do CytomX Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of CytomX Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in CytomX Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”